Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway

Abstract

The PTEN tumor suppressor is frequently mutated in human tumors. Loss of PTEN function is associated with constitutive survival signaling through the phosphatidylinositol-3 kinase/Akt pathway. Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed constitutive Akt activation in LNCaP prostate cancer cells and enhanced apoptosis induced by a broad range of apoptotic stimuli. PTEN expression sensitized cells to death receptor-mediated apoptosis induced by tumor necrosis factor, anti-Fas antibody, and TRAIL. PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide. PTEN-mediated apoptosis was accompanied by caspase-3 and caspase-8 activation and was inhibited by a broad specificity caspase inhibitor Z-VAD-fmk. Bcl-2 overexpression also blocked PTEN-mediated apoptosis. Lipid phosphatase activity of PTEN is required for apoptosis as the PTEN G129E mutant selectively deficient in lipid phosphatase activity was unable to sensitize cells to apoptosis. PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis as coexpression of a dominant negative FADD mutant blocked PTEN-mediated apoptosis. Since in death receptor signaling, FADD mediates activation of caspase-8, which in turn cleaves BID, and since caspase-8 is activated in PTEN-mediated apoptosis, we examined BID cleavage in PTEN-mediated apoptosis. PTEN facilitated BID cleavage after treatment with low doses of staurosporine and mitoxantrone. BID cleavage was inhibited by dominant negative FADD. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Ashkenazi A, Dixit VM . 1999 Curr. Opin. Cell. Biol. 11: 255–260

  • Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ . 1998 Mol. Cell. Biol. 18: 6353–6364

  • Budihardjo I, Oliver H, Lutter M, Luo X, Wang X . 1999 Annu. Rev. Cell. Dev. Biol. 15: 269–290

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC . 1998 Science 282: 1318–1321

  • Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM . 1996 J. Biol. Chem. 271: 4961–4965

  • Choi KB, Wong F, Harlan JM, Chaudhary PM, Hood L, Karsan A . 1998 J. Biol. Chem. 273: 20185–20188

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell 91: 231–241

  • Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA . 1999 Cancer Res. 59: 2551–2556

  • del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . 1997 Science 278: 687–689

  • Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP . 1998 Nat. Genet. 19: 348–355

  • Eskes R, Desagher S, Antonsson B, Martinou JC . 2000 Mol. Cell. Biol. 20: 929–935

  • Frisch SM . 1999 Curr. Biol. 9: 1047–1049

  • Gomez-Foix AM, Coats WS, Baque S, Alam T, Gerard RD, Newgard CB . 1992 J. Biol. Chem. 267: 25129–25134

  • Han Z, Pantazis P, Wyche JH, Kouttab N, Kidd VJ, Hendrickson EA . 2001 J. Biol. Chem. 276: 38748–38754

  • He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . 1998 Proc. Natl. Acad. Sci. USA 95: 2509–2514

  • Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J . 2000 Exp. Cell. Res. 256: 571–577

  • Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL . 1997 Nat. Med. 3: 402–408

  • Kulik G, Carson JP, Vomastek T, Overman K, Gooch BD, Srinivasula S, Alnemri E, Nunez G, Weber MJ . 2001 Cancer Res. 61: 2713–2719

  • Li H, Zhu H, Xu CJ, Yuan J . 1998 Cell 94: 491–501

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R . 1997a Science 275: 1943–1947

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997b Cell 91: 479–489

  • Luo X, Budihardjo I, Zou H, Slaughter C, Wang X . 1998 Cell 94: 481–490

  • Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS, Mayo MW . 2000 Mol. Cell. Biol. 20: 1626–1638

  • Maehama T, Dixon JE . 1998 J. Biol. Chem. 273: 13375–13378

  • Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG, Merlo A . 1999 Cancer Res. 59: 5479–5482

  • Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L . 1999 Cancer Res. 59: 382–390

  • McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR . 1999 Cancer Res. 59: 4291–4296

  • Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT . 1999 J. Biol. Chem. 274: 7987–7992

  • Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK . 1998 Proc. Natl. Acad. Sci. USA 95: 13513–13518

  • Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK . 1997 Proc. Natl. Acad. Sci. USA 94: 9052–9057

  • Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS . 2001 J. Biol. Chem. 276: 10767–10774

  • Newton K, Harris AW, Bath ML, Smith KG, Strasser A . 1998 EMBO J. 17: 706–718

  • Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R . 1999 Proc. Natl. Acad. Sci. USA 96: 1563–1568

  • Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R . 1995 Cancer Res. 55: 4438–4445

  • Rytomaa M, Martins LM, Downward J . 1999 Curr. Biol. 9: 1043–1046

  • Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME . 1998 EMBO J. 17: 1675–1687

  • Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958

  • Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y . 2001 Oncogene 20: 1852–1859

  • Sizemore N, Leung S, Stark GR . 1999 Mol. Cell. Biol. 19: 4798–4805

  • Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW . 1998 Cell 95: 29–39

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV . 1997 Nat. Genet. 15: 356–362

  • Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW . 1998a Curr. Biol. 8: 1169–1178

  • Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS . 1998b Cancer Res. 58: 204–209

  • Tang D, Lahti JM, Grenet J, Kidd VJ . 1999 J. Biol. Chem. 274: 7245–7252

  • Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK . 2001 J. Biol. Chem. 276: 38361–38369

  • Wang CY, Mayo MW, Baldwin Jr AS . 1996 Science 274: 784–787

  • Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ . 2000 Genes Dev. 14: 2060–2071

  • Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ . 2001 Science 292: 727–730

  • Weng LP, Brown JL, Eng C . 2001 Hum. Mol. Genet. 10: 599–604

  • Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL . 1998 Proc. Natl. Acad. Sci. USA 95: 5246–5250

  • Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL . 1998 Proc. Natl. Acad. Sci. USA 95: 15587–15591

  • Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW . 1998 Science 279: 1954–1958

Download references

Acknowledgements

This work was supported by grants from the Department of Defense Prostate Cancer Research Program (DAMD17-00-1-0037) and NIH (CA85772). We thank Ralph Buttyan, Marco Marcelli, Lily Wu, David Brenner, Peter Krammer and Charles Sawyers for reagents, and Marty Mayo, Al Baldwin, Chris Gregory and Charles Sawyers for discussions and reviewing the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Young E Whang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yuan, XJ., Whang, Y. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319–327 (2002). https://doi.org/10.1038/sj.onc.1205054

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205054

Keywords

This article is cited by

Search

Quick links